^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Small Lymphocytic Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Bendamustine, rituximab + ibrutinib (category 2B)...
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma...CLL/SLL without del(17p)/TP53 mutation...First-line therapy…Other recommended regimens…ibrutinib + rituximab (category 2B)....